Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Open-label, Randomized, Comparative Study of the Efficacy and Safety of RPH-002 and Erbitux® in Patients With Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

NCT07435324 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT07435324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07435324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Open-label, Randomized, Comparative Study of the Efficacy and Safety of RPH-002 and Erbitux® in Patients With Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Lead sponsor
R-Pharm
Phase
Phase 3
Overall status
Completed
Start date
August 8, 2024
Completion date
June 25, 2026
Enrollment
161 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma